Skip to main content

Table 2 Effect of SGLT2 inhibitors on clinical outcomes among participants with reduced eGFR

From: Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis

Outcome No. studies No. events Sample size HR (95% CI) I2, % PHeterogeneity PEgger test
Overall (eGFR < 60 mL/min/1.73m2)
 MACE 6 2102 20,106 0.82 (0.74–0.91) 8.6 0.363 0.810
 Kidney composite 4 530 16,480 0.65 (0.55–0.78) 0.0 0.645 0.771
 HHF 6 1125 20,106 0.61 (0.54–0.70) 0.0 0.740 0.099
 Cardiovascular death 5 834 18,299 0.86 (0.75–0.98) 0.0 0.912 0.363
 Fatal and nonfatal MI 4 320* 15,707 0.75 (0.63–0.90) 0.0 0.480 0.879
 Fatal and nonfatal stroke 4 190* 15,707 0.75 (0.55–1.01) 38.3 0.151 0.855
 All-cause mortality 3 837 13,668 0.93 (0.81–1.07) 0.0 0.638 0.147
eGFR < 45 mL/min/1.73m2**
 MACE 3 347 2437 0.75 (0.60–0.93) 0.0 0.797 0.921
 Kidney composite 2 225 1867 0.70 (0.54–0.92) 0.0 0.841 NA
 HHF 3 166 2437 0.60 (0.44–0.82) 0.0 0.522 0.193
 Cardiovascular death 3 191 2437 0.83 (0.62–1.11) 0.0 0.699 0.925
 Fatal and nonfatal MI 2 71 1124 0.70 (0.39–1.26) 28.3 0.238 NA
 Fatal and nonfatal stroke 2 38 1124 0.52 (0.23–1.17) 30.2 0.231 NA
 All-cause mortality 1 74 570 0.86 (0.54–1.38) NA NA NA
  1. *The number of MI and stroke events were not reported in SCORED and are therefore not included in the table. Likewise, the number of HHF/cardiovascular death events were not reported in SOLOIST-WHF and are not included in the table. CI indicates confidence interval, eGFR estimated glomerular filtration rate, HHF hospitalization for heart failure, MACE major adverse cardiovascular events, HR hazard ratio, MI myocardial infarction, NA not applicable, NR not reported, SCORED Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk, SGLT2 sodium-glucose cotransporter 2, SOLOIST-WHF Effect of Sotagliflozin on Cardiovascular Events in Patients with Type 2 Diabetes Post Worsening Heart Failure
  2. **The lower ends of eGFR ranged from 25 to 30 mL/min/1.73 m2